Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of M184V on the Virological Efficacy to Lamivudine/Dolutegravir

Next Previous
X
Search
Trial Profile

Impact of M184V on the Virological Efficacy to Lamivudine/Dolutegravir

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms LAMRES

    • Most Recent Events

    • 09 Feb 2023 Status changed from recruiting to completed.
    • 30 Oct 2021 Results (n=695) assessing the risk of virologic failure in a large cohort of virologically suppressed persons living with HIV (PLWH) with or without past M184V switched to DTG-3TC in the French DAT AIDS cohort, presented at the 18th European AIDS Conference.
    • 21 Jul 2021 Planned End Date changed from 31 Dec 2020 to 15 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top